Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation...

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Patient-Reported Outcomes

Background:

• Refractory Mycobacterium avium complex lung disease (MAC-LD) poses significant treatment challenges.
• Amikacin liposome inhalation suspension (ALIS) is a key therapy, but adverse events (AEs) can impact treatment adherence.

Purpose of the Study:

• To explore patient-identified strategies for managing AEs associated with ALIS.
• To understand how patients cope with and mitigate AEs in a real-world setting.

Main Methods:

• Semi-structured interviews were conducted with US patients receiving ALIS for refractory MAC-LD.
• Interview transcripts were analyzed to identify and categorize AE mitigation strategies and their perceived effectiveness.

Main Results:

• Twenty participants described 44 unique AE mitigation strategies.
• Strategies focused on preparing for treatment, preventing AE emergence, and persisting with treatment.
• Common strategies included utilizing patient support programs and managing localized irritation or fatigue.

Conclusions:

• A diverse range of patient-led AE mitigation strategies for ALIS treatment were identified.
• These findings can inform future research on AE management and support evidence-based recommendations for patients with MAC-LD.